SGLT2i are generally well-tolerated, but can cause side effects such as urinary tract infections and dehydration. If you are interested in learning more about SGLT2i, I recommend talking to your doctor. They can provide you with more information about the benefits and risks of these drugs and...
Methods The aim of this review is focusing on current trials of SGLT-2i with less side effects and improved patient compliance, which lead to different options such as using either a higher dose amount or dose frequency. Results With the acceleration of clinical studies, it would not be ...
This suggests that the side effects of SGLT-2i on the metabolism and nutrition system are also worthy of our attention. In our study, there was an equal proportion of men and women in the population that used SGLT2-i and had side effects (Supplementary Table 4). Age groups are mainly ...
Interestingly, SGLT2i are among the first antidiabetic drugs that have demonstrated the ability to reduce severe HF events and that have significant effects in mitigating each of these mechanisms (Table 1) [18,19,20,21], producing a combination of systemic and direct effects on the myocardium ...
9,10 In this study, we developed a pig model of AIC, testing various doxorubicin doses to induce AIC while minimizing mortality and systemic side effects. Intense efforts directed at identifying therapeutic strategies to prevent AIC have produced inconsistent results.11 Most interventions so far ...
For SGLT2i, suggested mechanisms include (but are not limited to): reduced levels of plasma plasminogen activator inhibitor-1 (PAI-1), leading to visceral fat area loss and a restored adipokine balance [52]; beneficial vascular effects via anti-inflammatory mechanisms, as indicated by reduced hi...
Clinicians should be aware of this rare side effect of SGLT2-i, to circumvent delays in patient management.doi:10.1136/dtb.2019.231104repRoss LeaderJake CowenSurya Panicker RajeevDrug and Therapeutics Bulletin
sglt2iSodium-glucose cotransporter 2 inhibitors (SGLT2i) use is associated with an increased risk of diabetic ketoacidosis (DKA). The clinical data regarding the use of SGLT2i and its potential side effects in oncology patients is limited. We are retrospectively reporting four oncology patients ...
We did not found any difference in older patients in the rate of CV events or death (Log rank 0.6) CONCLUSION Side effects of iSGLT2 were uncommon in our population, and age above 75 years was not associated with a higher incidence of AEs. GU tract infections, which were the most ...
Real-world studies are useful to examine the degree to which extent the results from RCTs could apply to patients outside the trials and also to assess long-term response and safety. The Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors (CVD-REAL) study enr...